acquired
Stage
About
Landos Biopharma develops NX-13, a first-in-class oral NLRX1 agonist in Phase 2 clinical trials, targeting moderate to severe ulcerative colitis and Crohn's disease by modulating immunometabolism and inflammation.
Explore Landos Biopharma's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.